Semaglutide behaves like human glucagon-like peptide-1 (GLP-1) in that it increments insulin discharge, in this manner expanding sugar digestion. It is disseminated as a metered subcutaneous infusion in a prefilled pen, or as an oral structure. One of its benefits over other antidiabetic drugs is that it has a long length of activity, so a once seven days infusion is adequate.